show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

UCERIS: Oral tablet, extended release

Also see:
  • Reported side effects
  • Daily life interactions

Available Strengths
Drug Image file DrugItem_16081.JPG
UCERIS 9mg ER Tablet
Salix Pharmaceuticals Inc, a wholly-owned subsidiary of Valeant
Pill Identification: MX9 

Frequently Asked Questions (FAQs) on UCERIS: Oral tablet, extended release

What is this medicine?

BUDESONIDE (bue DES oh nide) is a corticosteroid. It is used in the treatment of Crohn's disease and ulcerative colitis which are types of inflammatory bowel disease.

What should I tell my health care provider before I take this medicine?

How should I use this medicine?

What if I miss a dose?

What may interact with this medicine?

What should I watch for while using this medicine?

What side effects may I notice from receiving this medicine?

Where should I keep my medicine?

Drugs Related by Class to UCERIS: Oral tablet, extended release
Previous Class name
Class Name : Corticosteroids, Locally Acting Intestinal Antiinflammatory Agents

Related Brand Name Drugs :

Most Commonly Used Drugs by Class

Related Generic Drugs :

Next Class name
CVS Pharmacy Patient Statistics for UCERIS: Oral tablet, extended release
Usage by Gender
56.8%
43.2%
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage by Age
7.1%
31.96%
35.9%
25.04%
In-Depth Information on This Drug
Select a specific strength to visit the detail page where you'll find :
  • Reported side effects
  • Daily life interactions
Select a Strength
Patient Experiences with UCERIS

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.